- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00031057
Vitamin B Therapy for Hyperlactatemia
A Pilot Study of Oral B Vitamin Therapy for Asymptomatic or Mildly Symptomatic Hyperlactatemia in Patients on NRTIs
The purpose of this study is to see if vitamin B can treat mild hyperlactatemia (a higher than normal level of lactate in the blood) in patients who take nucleoside reverse transcriptase inhibitors (NRTIs).
Hyperlactatemia is a potentially life-threatening condition that can be associated with NRTI therapy. A lack of vitamin B may be related to the development of hyperlactatemia. However, no studies have been done to evaluate this. This study proposes that high doses of vitamin B may bring elevated lactate levels back to normal among patients taking NRTIs.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hyperlactatemia, with or without lactic acidosis, is a potentially life-threatening condition that appears to be associated with NRTI therapy. The natural history of lactate elevation as a complication of NRTI therapy is not clearly understood; however, some patients receiving these therapies experience a progressive increase in lactate to symptomatic levels. Deficiencies in thiamine (vitamin B1) and riboflavin (vitamin B2) have been implicated as cofactors in producing hyperlactatemia and lactic acidosis in NRTI-treated patients. A nontoxic intervention that could prevent or reverse advancing lactic acidosis and preserve NRTI use would be highly desirable. To date, no controlled studies have been done to examine the potential role of dietary intake, B vitamin deficiency, and B vitamin therapy on the pathogenesis and clinical course on NRTI-associated lactic acidosis. The hypothesis proposed is that high-dose vitamin B treatment can normalize elevated lactate levels among NRTI-exposed individuals with moderately elevated lactate levels.
This study consists of 2 steps: Step 1 (screening) and Step 2 (treatment). Patients are screened during Step 1 for sustained hyperlactatemia and Step 2 eligibility. Patients with sustained hyperlactatemia but no symptoms that indicate high risk of progression to lactic acidosis and with no plans to change existing NRTI-containing antiretroviral therapy may enter Step 2. A fasting, nonexercise, venous lactate level is obtained at Step 2 entry for use as a baseline measurement, and every patient receives high-dose oral vitamin B1 and B2 therapy for 4 weeks. Fasting, nonexercise, venous lactate levels are measured at Weeks 1, 2, and 4 to observe the kinetics of changes in lactate levels on study treatment.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- Beth Israel Med Ctr
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 275997215
- Univ of North Carolina
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve Univ
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients may be eligible for this study if they:
- Are at least 13 years old.
- Give written informed consent. Patients less than 18 years old must have written informed consent of a parent or guardian.
- Are HIV-infected.
- Have been using anti-HIV therapy containing an NRTI for at least 4 weeks before study entry and have no plan to change their anti-HIV treatment during the study.
- Fulfill at least 1 criterion listed in protocol indicating an elevated venous lactate measurement.
Exclusion Criteria
Patients may not be eligible for this study if they:
- Have inflammation of the pancreas 30 days before study entry.
- Have other medical conditions that may result in elevated lactate levels.
- Are pregnant or breast-feeding.
- Started experiencing certain symptoms within 30 days prior to study entry that might be due to hyperlactatemia.
- Have used metformin within 30 days prior to study entry.
- Have used high-dose vitamin supplements containing vitamin B1 (thiamine) and/or vitamin B2 (riboflavin) within 30 days prior to study entry.
- Have used certain dietary supplements within 30 days prior to study entry.
- Use chemotherapy.
- Are receiving any unknown therapies or medications.
- Are allergic or sensitive to the study drug.
- Had an illness within 30 days before study entry that, in the opinion of the investigator, would interfere with the study.
- Use drugs or alcohol that, in the opinion of the investigator, would interfere with the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Investigators
- Study Chair: Christopher Pilcher
Publications and helpful links
Study record dates
Study Major Dates
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACTG A5129
- AACTG A5129
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Thiamine hydrochloride
-
Menzies School of Health ResearchCompleted
-
Mount Saint Vincent UniversityUniversity of Oregon; Bill and Melinda Gates Foundation; Helen Keller International and other collaboratorsCompleted
-
University of OxfordEnrolling by invitation
-
Mayo ClinicARUP Laboratories; Eastern Mennonite MissionsCompleted
-
UNC Lineberger Comprehensive Cancer CenterRising Tide FoundationCompletedDelirium | Hematopoietic Stem Cell Transplantation | Thiamine DeficiencyUnited States
-
Beth Israel Deaconess Medical CenterCompletedSepsis | Kidney Injury | Thiamine DeficiencyUnited States
-
Mahidol UniversityCompleted
-
Meshalkin Research Institute of Pathology of CirculationCompletedCardiac SurgeryRussian Federation
-
Mashhad University of Medical SciencesCompletedChronic Heart FailureIran, Islamic Republic of
-
Meir Medical CenterCompleted